Posted by Michael Wonder on 28 May 2025
Experimental Drug Development Centre granted US FDA fast track designation for antibody-drug conjugate EBC-129 to treat pancreatic ductal adenocarcinoma
28 May 2025 - EBC-129 is the first made in Singapore antibody-drug conjugate to enter clinical development.
The Experimental Drug Development Centre, Singapore's national platform for drug discovery and development, today announced that the US FDA has granted fast track designation for EBC-129 for the treatment of pancreatic ductal adenocarcinoma.
